Validation of surface plasmon resonance screening of a diverse chemical library for the discovery of protein tyrosine phosphatase 1b binders.

We investigated the suitability of surface plasmon resonance (SPR) for providing quantitative binding information from direct screening of a chemical library on protein tyrosine phosphatase 1b (PTP1B). The experimental design was established from simulations to detect binding with K(D) < 10⁻⁴ M. The 1120 compounds (cpds) were injected sequentially at concentrations [C(cpd)] of 0.5 or 10 μM over various target surfaces. An optimized evaluation procedure was applied. More than 90% of cpds showed no detectable signal in four screens. The 30 highest responders at C(cpd)=10 μM, of which 25 were selected in at least one of three screens at C(cpd)=0.5 μM, contained 22 promiscuous binders and 8 potential PTP1B-specific binders with K(D) ~10⁻⁵ M. Inhibition of PTP1B activity was assayed and confirmed for 6 of these, including sanguinarine, a known PTP1B inhibitor. C(cpd) dependence studies fully confirmed screening conclusions. The quantitative consistency of SPR data led us to propose a structure-activity relationship (SAR) model for developing selective PTP1B inhibitors based on the ranking of 10 arylbutylpiperidine analogs.

[1]  Andrew L Hopkins,et al.  Fragment screening by surface plasmon resonance. , 2010, ACS medicinal chemistry letters.

[2]  D. Lawrence,et al.  Probing the Molecular Basis for Potent and Selective Protein-tyrosine Phosphatase 1B Inhibition* , 2002, The Journal of Biological Chemistry.

[3]  Å. Frostell-Karlsson,et al.  Studies of small molecule interactions with protein phosphatases using biosensor technology. , 2006, Analytical biochemistry.

[4]  D. Myszka,et al.  Improving biosensor analysis , 1999, Journal of molecular recognition : JMR.

[5]  T Neumann,et al.  SPR-based fragment screening: advantages and applications. , 2007, Current topics in medicinal chemistry.

[6]  G. Stier,et al.  Defining the minimal interacting regions of the tight junction protein MAGI-1 and HPV16 E6 oncoprotein for solution structure studies. , 2008, Protein expression and purification.

[7]  B. Persson,et al.  Studies of interactions with weak affinities and low‐molecular‐weight compounds using surface plasmon resonance technology , 1998, Journal of molecular recognition : JMR.

[8]  G. Siegal,et al.  Target Immobilization as a Strategy for NMR-Based Fragment Screening , 2010, Journal of biomolecular screening.

[9]  Anthony M Giannetti,et al.  Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. , 2008, Journal of medicinal chemistry.

[10]  H Roos,et al.  Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. , 2000, Journal of medicinal chemistry.

[11]  L. Vrang,et al.  Screening for NNRTIs with Slow Dissociation and High Affinity for a Panel of HIV-1 RT Variants , 2009, Journal of biomolecular screening.

[12]  M. Tremblay,et al.  Modulation of insulin signaling by protein tyrosine phosphatases , 2000, Journal of Molecular Medicine.

[13]  U Helena Danielson,et al.  Fragment library screening and lead characterization using SPR biosensors. , 2009, Current topics in medicinal chemistry.

[14]  Pascal Rigollier,et al.  Fragment-Based Screening by Biochemical Assays , 2010, Journal of biomolecular screening.

[15]  M. Hämäläinen,et al.  Biosensor analysis of drug-target interactions: direct and competitive binding assays for investigation of interactions between thrombin and thrombin inhibitors. , 2000, Analytical biochemistry.

[16]  Walter Huber,et al.  A new strategy for improved secondary screening and lead optimization using high‐resolution SPR characterization of compound–target interactions , 2005, Journal of molecular recognition : JMR.

[17]  Walter Huber,et al.  Fragment-Based Screening Using Surface Plasmon Resonance Technology , 2009, Journal of biomolecular screening.

[18]  Magnus Björsne,et al.  Label-Free Primary Screening and Affinity Ranking of Fragment Libraries Using Parallel Analysis of Protein Panels , 2008, Journal of biomolecular screening.

[19]  Claudio Dalvit,et al.  NMR methods in fragment screening: theory and a comparison with other biophysical techniques. , 2009, Drug discovery today.

[20]  Tomas Lundqvist The devil is still in the details--driving early drug discovery forward with biophysical experimental methods. , 2005, Current opinion in drug discovery & development.

[21]  Andreas Vogt,et al.  The Benzo[c]phenanthridine Alkaloid, Sanguinarine, Is a Selective, Cell-active Inhibitor of Mitogen-activated Protein Kinase Phosphatase-1* , 2005, Journal of Biological Chemistry.

[22]  Constantine Kreatsoulas,et al.  Algorithms for the automated selection of fragment-like molecules using single-point surface plasmon resonance measurements. , 2010, Analytical biochemistry.